FNF Overview - FNF's total revenue for FY2022 was $116 billion[6] - FNF holds a 31% title market share[6] - FNF holds 1 or 2 market share in 44 states[7, 17] Title Segment Performance - FNF's adjusted pre-tax title margin in 1Q23 was 100%[28, 33, 63, 79, 90] - FNF's title revenue in 1Q23 was $91 billion[28] - FNF consistently holds top market share in residential purchase, refinance, and commercial markets[12] F&G Segment Performance - F&G's assets under management reached $45 billion in 1Q23, an 18% year-over-year increase[40, 41, 63, 65] - F&G's gross sales in 1Q23 grew by 27% year-over-year to $33 billion[40, 41, 63, 65] - F&G's adjusted net earnings for 2022 were $317 million[43] Financial Position - FNF's debt-to-capitalization ratio, excluding AOCI, was 285% as of March 31, 2023[60, 61] - FNF held over $800 million in holding company cash and short-term investments as of March 31, 2023[61, 65]

Sustainable Long-Term Growth from Commercial Pharmaceutical Assets Nasdaq: ASRT May 2025 Disclaimers The statements in this communication include forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking statements speak only as of the date they are made or as of the dates indicated in the statements and should not be relied upo ...

Concrete Pumping Holdings, Inc. (NASDAQ:BBCP) Q2 2025 Earnings Conference Call June 5, 2025 5:00 PM ET Company Participants Bruce F. Young - President, CEO & Director Iain Humphries - CFO, Secretary & Director Conference Call Participants Benjamin Luke McFadden - William Blair & Company L.L.C., Research Division Jean Franco Veliz - D.A. Davidson & Co., Research Division Cody Slach - Gateway Group, Inc. Operator Good afternoon, everyone, and thank you for participating in today's conference call to discuss C ...

FIRST QUARTER 2025 Investor Presentation Safe Harbor Statement Under The Private Securities Litigation Reform Act Of 1995 This presentation and related statements by management contain forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), which represent management's expectations or beliefs concerning future events, including, without limitation, second fiscal quarter and annual fiscal 2025 results. Words such as "outlook," "estimate," "project," "plan ...

Group 1 - The conference call is for Kohl's Corporation's First Quarter 2025 earnings, indicating a focus on financial performance and future initiatives [1] - Trevor Novotny, Senior Manager of Investor Relations, is leading the call, suggesting a structured approach to investor communication [1] - The call includes a question-and-answer session, highlighting engagement with analysts and investors [1] Group 2 - Forward-looking statements regarding projected financial results and future initiatives are made, which are subject to risks and uncertainties [2] - The company emphasizes that actual results may differ materially from projections due to various risks outlined in their annual report [2] - Non-GAAP financial measures may be referenced during the call, indicating a focus on alternative financial metrics for analysis [3]

Q1 Results Presentation May 29, 2025 1 Cautionary Statement Regarding Forward-Looking Information This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our 2025 a ...

Record first quarter net sales of $1.1 billion, up 8% from last year, exceeding outlookNet sales growth across regions, with Americas up 7%, EMEA up 12% and APAC up 5%Brand performance led by Hollister brands’ growth of 22% with Abercrombie brands down 4% compared to last yearProfitability exceeds company outlook with operating margin of 9.3%, earnings per share of $1.59Repurchased 2.6 million shares for $200 million, representing 5% of shares outstanding at February 1, 2025 NEW ALBANY, Ohio, May 28, 2025 ( ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $8,600,000, representing a 9% increase from the same period last year [5][12] - Net loss for Q1 2025 was $4,200,000 or $0.47 per share, compared to a net loss of $10,400,000 or $2.88 per share for the prior year [15] - Adjusted EBITDA decreased from $4,600,000 in Q1 2024 to $4,400,000 in Q1 2025 [15][16] Business Line Data and Key Metrics Changes - Ameluz sales increased by $500,000 due to a higher unit price and the launch of the RotoLED XL lamp, which generated $200,000 in sales [12] - Total operating expenses decreased to $13,100,000 in Q1 2025 from $13,400,000 in Q1 2024 [12][13] - Cost of revenues decreased by $900,000 or 22.1% compared to last year, attributed to a reduced cost structure under the Ameluz license [13] Market Data and Key Metrics Changes - The company achieved a significant milestone with the granting of a patent for a new formulation of Ameluz, providing protection until December 2043 [6][7] - The enrollment of the final patient in the Phase three clinical trial for Ameluz was announced, aiming to extend the label for treatment beyond the face and scalp [8] Company Strategy and Development Direction - The company aims to achieve record revenues in 2025 without increasing costs, supported by past investments and sales force effectiveness [5] - Future goals include expanding Ameluz's applications to treat superficial basal cell carcinoma and moderate to severe acne, addressing significant medical needs [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving breakeven as quickly as possible, highlighting improved gross profit and reduced operating expenses [11] - The company is committed to exploring additional applications for Ameluz beyond actinic keratosis, indicating a proactive approach to growth [9] Other Important Information - Cash and cash equivalents as of March 31, 2025, were $1,800,000, down from $5,900,000 as of December 31, 2024 [16] - Inventory on hand was $6,500,000 compared to $6,600,000 as of December 31, 2024 [16] Q&A Session Summary Question: How many LAMP units were sold in Q1 2025? - The company placed 18 XL lamps in Q1 2025 [19][20] Question: Is there any sales force attrition affecting expenses? - There has been some turnover, but the company is committed to reorganizing the team for efficiency [24] Question: What is the status of reimbursement for the three-tube indication? - The company has ensured that Medicare covers the three-tube indication, with no reported refusals from doctors [29]

Ondas Holdings Inc. (NASDAQ:ONDS) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Eric Brock - Chairman of the Board, President and Chief Executive Officer Neil Laird - Interim Chief Financial Officer, Treasurer and Secretary of the Company Oshri Lugassy - Co CEO, Autonomous Systems Markus Nottelmann - CEO, Ondas Networks Conference Call Participants Maxwell Michaelis - Lake Street Capital Markets Glenn Mattson - Ladenburg Thalmann Matthew Galinko - Maxim Group Mike Latimore - ...

Gauzy Ltd. (NASDAQ:GAUZ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Daniel Scott - SVP, IR, ICR Eyal Peso - Co-Founder and CEO Meir Peleg - CFO Conference Call Participants Dan Levy - Barclays Itay Michaeli - TD Cowen Operator Good morning and welcome to Gauzy Limited First Quarter 2025 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A. At this time, I would like to turn the conference over to Dan Scott, In ...